Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response

Inhibitors of poly(ADP-ribose) polymerase (PARPi) have entered the clinic for the treatment of patients with cancers that lack homology-directed DNA repair, but drug resistance remains a clinical hurdle. Recent advances in the identification of PARPi resistance mechanisms have yielded a better under...

Descripción completa

Detalles Bibliográficos
Autores principales: Francica, Paola, Rottenberg, Sven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309079/
https://www.ncbi.nlm.nih.gov/pubmed/30593284
http://dx.doi.org/10.1186/s13073-018-0612-8
_version_ 1783383335340343296
author Francica, Paola
Rottenberg, Sven
author_facet Francica, Paola
Rottenberg, Sven
author_sort Francica, Paola
collection PubMed
description Inhibitors of poly(ADP-ribose) polymerase (PARPi) have entered the clinic for the treatment of patients with cancers that lack homology-directed DNA repair, but drug resistance remains a clinical hurdle. Recent advances in the identification of PARPi resistance mechanisms have yielded a better understanding of DNA end protection and the relevance of endogenous poly(ADP-ribose) glycohydrolase, highlighting new vulnerabilities.
format Online
Article
Text
id pubmed-6309079
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63090792019-01-03 Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response Francica, Paola Rottenberg, Sven Genome Med Comment Inhibitors of poly(ADP-ribose) polymerase (PARPi) have entered the clinic for the treatment of patients with cancers that lack homology-directed DNA repair, but drug resistance remains a clinical hurdle. Recent advances in the identification of PARPi resistance mechanisms have yielded a better understanding of DNA end protection and the relevance of endogenous poly(ADP-ribose) glycohydrolase, highlighting new vulnerabilities. BioMed Central 2018-12-28 /pmc/articles/PMC6309079/ /pubmed/30593284 http://dx.doi.org/10.1186/s13073-018-0612-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Comment
Francica, Paola
Rottenberg, Sven
Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
title Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
title_full Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
title_fullStr Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
title_full_unstemmed Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
title_short Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
title_sort mechanisms of parp inhibitor resistance in cancer and insights into the dna damage response
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6309079/
https://www.ncbi.nlm.nih.gov/pubmed/30593284
http://dx.doi.org/10.1186/s13073-018-0612-8
work_keys_str_mv AT francicapaola mechanismsofparpinhibitorresistanceincancerandinsightsintothednadamageresponse
AT rottenbergsven mechanismsofparpinhibitorresistanceincancerandinsightsintothednadamageresponse

Ejemplares similares